Advertisement
Loading...

BrainsWay Ltd.

BRSYFPNK
Healthcare
Medical - Devices
$16.84
$0.00(0.00%)
U.S. Market opens in 6h 36m
Advertisement

BrainsWay Ltd. Fundamental Analysis

BrainsWay Ltd. (BRSYF) shows moderate financial fundamentals with a PE ratio of 72.90, profit margin of 15.68%, and ROE of 12.28%. The company generates $0.1B in annual revenue with strong year-over-year growth of 37.83%.

Key Strengths

Cash Position11.56%
PEG Ratio0.67
Current Ratio3.34

Areas of Concern

No major concerns flagged.
We analyze BRSYF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 73.6/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.

Fundamental Health Score

B
73.6/100

We analyze BRSYF's fundamental strength across five key dimensions:

Efficiency Score

Weak

BRSYF struggles to generate sufficient returns from assets.

ROA > 10%
7.54%

Valuation Score

Moderate

BRSYF shows balanced valuation metrics.

PE < 25
72.90
PEG Ratio < 2
0.67

Growth Score

Moderate

BRSYF shows steady but slowing expansion.

Revenue Growth > 5%
37.83%
EPS Growth > 10%
1.56%

Financial Health Score

Excellent

BRSYF maintains a strong and stable balance sheet.

Debt/Equity < 1
0.09
Current Ratio > 1
3.34

Profitability Score

Moderate

BRSYF maintains healthy but balanced margins.

ROE > 15%
12.28%
Net Margin ≥ 15%
15.68%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is BRSYF Expensive or Cheap?

P/E Ratio

BRSYF trades at 72.90 times earnings. This suggests a premium valuation.

72.90

PEG Ratio

When adjusting for growth, BRSYF's PEG of 0.67 indicates potential undervaluation.

0.67

Price to Book

The market values BrainsWay Ltd. at 8.48 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

8.48

EV/EBITDA

Enterprise value stands at 60.59 times EBITDA. This signals the market has high growth expectations.

60.59

How Well Does BRSYF Make Money?

Net Profit Margin

For every $100 in sales, BrainsWay Ltd. keeps $15.68 as profit after all expenses.

15.68%

Operating Margin

Core operations generate 10.23 in profit for every $100 in revenue, before interest and taxes.

10.23%

ROE

Management delivers $12.28 in profit for every $100 of shareholder equity.

12.28%

ROA

BrainsWay Ltd. generates $7.54 in profit for every $100 in assets, demonstrating efficient asset deployment.

7.54%

Following the Money - Real Cash Generation

Operating Cash Flow

BrainsWay Ltd. generates strong operating cash flow of $14.89M, reflecting robust business health.

$14.89M

Free Cash Flow

BrainsWay Ltd. generates strong free cash flow of $12.02M, providing ample flexibility for dividends, buybacks, or growth.

$12.02M

FCF Per Share

Each share generates $0.30 in free cash annually.

$0.30

FCF Yield

BRSYF converts 2.11% of its market value into free cash.

2.11%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

72.90

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.67

vs 25 benchmark

P/B Ratio

Price to book value ratio

8.48

vs 25 benchmark

P/S Ratio

Price to sales ratio

12.008

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.09

vs 25 benchmark

Current Ratio

Current assets to current liabilities

3.34

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.12

vs 25 benchmark

ROA

Return on assets percentage

0.08

vs 25 benchmark

ROCE

Return on capital employed

0.06

vs 25 benchmark

How BRSYF Stacks Against Its Sector Peers

MetricBRSYF ValueSector AveragePerformance
P/E Ratio72.9028.32 Worse (Expensive)
ROE12.28%733.00% Weak
Net Margin15.68%-53055.00% (disorted) Strong
Debt/Equity0.090.38 Strong (Low Leverage)
Current Ratio3.344.03 Strong Liquidity
ROA7.54%-19488.00% (disorted) Weak

BRSYF outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews BrainsWay Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

50.67%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

190.20%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

898.53%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ